Form 4 for ADMA ADMA BIOLOGICS, INC.
Accepted 2025-06-16 00:00:00 ET · period of report 2025-06-12 · accession 0001140361-25-022713 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2025-06-16 | 2025-06-13 | ADMA | ELMS STEVE | Dir | M - OptEx | $3.43 | +332.7K | 207.7K | New | +$1.14M |
| DM | 2025-06-16 | 2025-06-13+ | ADMA | ELMS STEVE | Dir | S - Sale+OE | $20.48 | -332.7K | 282.1K | -54% | -$6.81M |
| DI | 2025-06-16 | 2025-06-12 | ADMA | ELMS STEVE | Dir | S - Sale+OE | $21.69 | -92.9K | 2.03M | -4% | -$2.02M |
| DM | 2025-06-16 | 2025-06-13 | ADMA | ELMS STEVE | Dir | M - OptEx | $0.00 | -332.7K | 0 | -100% | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2025-06-13 | M | A | 37,541 | $5.40 | 420,010 | D | — | — | |
| 2 | Common | Common Stock | 2025-06-16 | S | D | 194,749 | $20.24 | 87,330 | D | — | — | (F5) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.02 to $20.40, inclusive. (F6) Includes, as of the transaction date, (i) 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the reporting person's continued service as of such vesting date and (ii) 76,441 shares of common stock owned by the reporting person. |
| 3 | Common | Common Stock | 2025-06-13 | S | D | 137,931 | $20.82 | 282,079 | D | — | — | (F3) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $20.52 to $21.39, inclusive. (F4) Includes, as of the transaction date, (i) 10,889 RSUs granted on February 19, 2025, which will vest fully on February 19, 2026, subject to the reporting person's continued service as of such vesting date and (ii) 271,190 shares of common stock owned by the reporting person. |
| 4 | Common | Common Stock | 2025-06-13 | M | A | 53,837 | $3.66 | 160,167 | D | — | — | |
| 5 | Common | Common Stock | 2025-06-13 | M | A | 17,500 | $4.91 | 177,667 | D | — | — | |
| 6 | Common | Common Stock | 2025-06-12 | S | D | 92,941 | $21.69 | 2,031,730 | I See footnote | — | — | (F1) The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $21.37 to $22.17, inclusive. The reporting person undertakes to provide to ADMA Biologics, Inc. (the "Issuer"), any securityholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (1), (3) and (5). (F2) These shares are owned by Aisling Capital II LP ("Aisling"), which is a fund that was established in 2007 with a 10-year life. Mr. Elms is Aisling's designee for nomination to the Board. As a Managing Member of Aisling Capital Partners, LLC ("Aisling Partners"), a control person of Aisling, and as a member of the investment committee of Aisling Capital Partners, LP ("Aisling GP"), Mr. Elms may be deemed to be the beneficial owner of shares of common stock owned of record by Aisling. Mr. Elms disclaims beneficial ownership of Aisling's investment in the Company and Aisling Partners' ownership of the Company's options, except to the extent of his pecuniary interest therein. |
| 7 | Common | Common Stock | 2025-06-13 | M | A | 9,000 | $5.96 | 96,330 | D | — | — | |
| 8 | Common | Common Stock | 2025-06-13 | M | A | 10,000 | $5.00 | 106,330 | D | — | — | |
| 9 | Common | Common Stock | 2025-06-13 | M | A | 51,630 | $3.35 | 382,469 | D | — | — | |
| 10 | Common | Common Stock | 2025-06-13 | M | A | 53,172 | $1.67 | 330,839 | D | — | — | |
| 11 | Common | Common Stock | 2025-06-13 | M | A | 55,000 | $2.35 | 277,667 | D | — | — | |
| 12 | Common | Common Stock | 2025-06-13 | M | A | 15,000 | $2.92 | 222,667 | D | — | — | |
| 13 | Common | Common Stock | 2025-06-13 | M | A | 30,000 | $3.89 | 207,667 | D | — | — | |
| 14 | Derivative | Stock Option (Right to Buy) | 2025-06-13 | M | D | 15,000 | $0.00 | 0 | D | $2.92 · — to 2030-02-28 | 15,000 Common Stock | (F8) These options vested in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. |
| 15 | Derivative | Stock Option (Right to Buy) | 2025-06-13 | M | D | 51,630 | $0.00 | 0 | D | $3.35 · — to 2033-03-06 | 51,630 Common Stock | (F8) These options vested in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. |
| 16 | Derivative | Stock Option (Right to Buy) | 2025-06-13 | M | D | 37,541 | $0.00 | 0 | D | $5.40 · — to 2034-02-26 | 37,541 Common Stock | (F8) These options vested in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. |
| 17 | Derivative | Stock Option (Right to Buy) | 2025-06-13 | M | D | 9,000 | $0.00 | 0 | D | $5.96 · — to 2026-01-28 | 9,000 Common Stock | (F7) These options vested in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. |
| 18 | Derivative | Stock Option (Right to Buy) | 2025-06-13 | M | D | 10,000 | $0.00 | 0 | D | $5.00 · — to 2027-02-14 | 10,000 Common Stock | (F7) These options vested in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. |
| 19 | Derivative | Stock Option (Right to Buy) | 2025-06-13 | M | D | 53,837 | $0.00 | 0 | D | $3.66 · — to 2027-06-06 | 53,837 Common Stock | (F7) These options vested in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. |
| 20 | Derivative | Stock Option (Right to Buy) | 2025-06-13 | M | D | 17,500 | $0.00 | 0 | D | $4.91 · — to 2028-06-22 | 17,500 Common Stock | (F7) These options vested in twenty-four equal monthly installments, becoming fully vested on the two year anniversary of the date of grant. |
| 21 | Derivative | Stock Option (Right to Buy) | 2025-06-13 | M | D | 30,000 | $0.00 | 0 | D | $3.89 · — to 2029-03-13 | 30,000 Common Stock | (F8) These options vested in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. |
| 22 | Derivative | Stock Option (Right to Buy) | 2025-06-13 | M | D | 55,000 | $0.00 | 0 | D | $2.35 · — to 2031-02-25 | 55,000 Common Stock | (F8) These options vested in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. |
| 23 | Derivative | Stock Option (Right to Buy) | 2025-06-13 | M | D | 53,172 | $0.00 | 0 | D | $1.67 · — to 2032-03-07 | 53,172 Common Stock | (F8) These options vested in twelve equal monthly installments, becoming fully vested on the one-year anniversary of the date of grant. |